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A B S T R A C T
Background: In Brazil, it is estimated that approximately 27% of women of childbearing age use oral 
contraceptives (OC). The presentation and clinical course of acute myocardial infarction (AMI) in these 
women has yet to be described in Brazil. The aim of this study was to analyze the clinical profile, angiographic 
characteristics, technical aspects of the procedure, and the outcomes in women using OC who had an AMI and 
were submitted to primary percutaneous coronary intervention (PCI).
Methods: Women aged < 55 years who had acute ST segment elevation myocardial infarct and were referred to 
primary PCI were sequentially included and categorized into two groups: with and without current use of OC. 
Results: We have included 257 patients, of whom 19 (7.4%) used OC. These patients were younger (42.3 ± 6.2 
years vs. 48.4 ± 5.7 years; p < 0.001), with fewer traditional risk factors for coronary artery disease, but had 
higher serum levels of C-reactive protein and fibrinogen. The delta T was similar (4.00 [1.25 to 6.86] hours vs. 
4.50 [2.50 to 7.64] hours; p = 0.54), but the door-to-balloon time was longer in patients taking OC (1.41 [0.58 to 
1.73] hours vs. 1.16 [0.91 to 1.51] hour, p = 0.02). These patients were more frequently submitted to thrombus 
aspiration (52.6% vs. 25.6%; p = 0.04). After the index event, they had no atherothrombotic outcomes in up to 2 
years of follow-up (0 vs. 15.2%; p = 0.08).
Conclusions: In this study, different clinical profiles and outcomes were found among women of reproductive 
age, users or non-users of OC, and submitted to primary PCI. Studies with a larger number of patients are 
required to confirm these results. 
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Impacto do uso de anticoncepcional oral nas características e na evolução clínica 
de mulheres submetidas à intervenção coronariana percutânea primária
R E S U M O
Introdução: Em nosso, país estima-se que aproximadamente 27% das mulheres em idade fértil utilizem 
anticoncepcional oral (ACO). A apresentação e a evolução clínica do infarto agudo do miocárdio (IAM) nessas 
mulheres ainda não foi descrita em nosso meio. O objetivo do presente estudo foi analisar o perfil clínico, as 
características angiográficas, os aspectos técnicos do procedimento e os desfechos de usuárias de ACO que 
tiveram IAM e foram encaminhadas à intervenção coronariana percutânea (ICP) primária. 
Métodos: Mulheres < 55 anos que apresentaram IAM com supradesnivelamento do segmento ST e foram 
encaminhadas à ICP primária foram sequencialmente incluídas e categorizadas em dois grupos: com e sem uso 
atual de ACO. 
Resultados: Incluímos 257 pacientes, sendo que 19 (7,4%) usavam ACO. Estas eram mais jovens (42,3 ± 6,2 anos 
vs. 48,4 ± 5,7 anos; p < 0,001), com menos fatores de risco tradicionais para doença arterial coronariana, mas 
apresentavam proteína C-reativa fibrinogênio séricos mais elevados. O delta T foi semelhante (4,00 [1,25 a 
6,86] horas vs. 4,50 [2,50 a 7,64] horas; p = 0,54), mas o tempo porta-balão foi maior nas pacientes em uso de 
ACO (1,41 [0,58 a 1,73] hora vs. 1,16 [0,91 a 1,51] hora; p = 0,02). Estas pacientes foram mais frequentemente 
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Introduction
Acute myocardial infarction (AMI) affects more men than wo-
men. In women, during the reproductive years, the pathophysio-
logy of the event is more often related to thrombosis.1 Among the 
known risk factors for thrombosis is the use of oral contracepti-
ves (OC). This r isk is increased in patients with associated 
conditions, such as smoking, hypertension, obesity, and dyslipi-
demia.2 The association between venous thrombosis and the use 
of OC is well defined, and there are several studies showing an 
increased risk of AMI and ischemic stroke.2-4
In Brazil, it is estimated that approximately 27% of women of chil-
dbearing age use OC.5 The presentation and clinical course of AMI in 
these women has not been described in Brazil, which would be use-
ful to help doctors and patients with the management of this condi-
tion. The aim of this study was to analyze the clinical profile, 
angiographic characteristics, technical aspects of the procedure, 
and the outcomes in women using OC that had an AMI and were 
submitted to primary percutaneous coronary intervention (PCI).
Methods
Patients 
All women aged < 55 years who had an acute ST segment eleva-
tion myocardial infarction (STEMI) and were referred to primary 
PCI from 1 December 2009 to 30 May 2015, were considered for the 
study. Exclusion criteria were delta T > 12 hours and refusal to par-
ticipate. Patients were categorized into two groups: with and wi-
thout current use of OC, based on the information obtained from 
medical records.
STEMI was defined according to the following criteria: presence 
of typical pain at rest associated with ST-segment elevation of at 
least 1 mm in two contiguous leads in the frontal plane, or 2 mm in 
the horizontal plane.
The study was approved by the Ethics Committee of the institu-
tion and all patients signed an informed consent form.
Procedures
The primary PCI procedures were performed as described in the 
literature.6 Specific technical aspects, such as access route, drug ad-
ministration, type of stent, and thrombus aspiration were at the dis-
cretion of the interventionists. 
Trained researchers performed the clinical interviews. Demo-
graphic data, risk factors for ischemic heart disease, past medical 
history, and clinical presentation of the event were collected. La-
boratory assessment was performed according to the routine of 
the institution.
Angiographic evaluations were performed with a previously vali-
dated digital electronic system (Siemens Axiom Artis, Siemens, Mu-
nich, Germany) and the following variables were assessed: number 
submetidas à tromboaspiração (52,6% vs. 25,6%; p = 0,04). Após o evento índice, elas não apresentaram desfechos 
aterotrombóticos em até 2 anos de acompanhamento (0 vs. 15,2%; p = 0,08). 
Conclusões: Neste estudo, encontramos perfil clínico e desfechos diferentes entre mulheres em idade 
reprodutiva, usuárias ou não de ACO, e submetidas à ICP primária. Estudos com maior número de pacientes são 
necessários para confirmar tais resultados.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of vessels with > 50% luminal stenosis, treated coronary artery, and 
presence of thrombus and angiographic calcification.
Outcomes and definitions
Patients were followed during the in-hospital period and the 
occurrence of major cardiovascular events (MACE) and their in-
dividual components cardiovascular death, recurrent AMI or 
new PCI, stroke, stent thrombosis, major bleeding, minor blee-
ding, and acute renal failure were recorded. The follow-up at 1 
year and 2 years after the event was carried out by telephone 
contact, recording the occurrence of MACE, cardiovascular dea-
th, recurrent myocardial infarction, ischemic stroke, and stent 
thrombosis.
Recurrent AMI was considered when ST elevation > 0,1 mV re-
curs, or new Q waves appear, in at least two contiguous leads, par-
ticularly when associated with ischemic symptoms for 20 minutes 
or longer. Stroke was defined as focal neurological deficit of sudden 
onset, irreversible, in the first 24 hours. Stent thrombosis was clas-
sified as sudden occlusion of the treated vessel, confirmed by an-
giography. Major bleeding was defined as the occurrence of 
clinically evident bleeding with a decrease in hemoglobin levels > 5 
g/dL or hematocrit > 15%, or development of hemorrhagic stroke, or 
coronary artery bypass graft-related bleeding with transfusion ≥ 5 
packed red blood cells in 48 hours postoperatively or draining 
> 1 mL in 24 hours. Minor bleeding was considered as clinically 
evident bleeding with a decrease in hemoglobin between 3 and 5 g/
dL and hematocrit levels between 9 and 15%. Acute renal failure 
was defined as an increase in serum creatinine ≥ 0.3 mg/dL within 
48 hours, or a 1.5-fold increase in the basal levels, or urine output 
 < 0.5 mL/kg/hour for 6 hours.
Statistical analysis
Categorical variables were described as absolute numbers and 
percentages, and compared using the Chi-squared test or Fisher's 
exact test, as appropriate. Continuous variables were described as 
mean and standard deviation and compared using the t-test. Conti-
nuous variables with non-normal distribution were expressed as 
median and interquartile range and compared using the Mann-
-Whitney test. The Statistical Package for Social Sciences (SPSS) v. 
23.0 for Windows was used and statistical significance was defined 
by two-tailed p < 0.05. 
Results
During the study period, 257 patients were included, 19 
(7.4%) using OC and 238 who do not make use of OC. Patients 
using OC were younger (42.3 ± 6.2 years vs. 48.4 ± 5.7 years; p < 
0.001), less frequently had arterial hypertension and diabetes, 
and had a smaller abdominal circumference (Table 1). The time 
of arrival at the hospital after symptom onset was similar be-
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Table 1
Clinical characteristics.
Characteristics OC 
n = 19
Without OC 
n = 238
p-value
Age, years 42.3 ± 6.2 48.4 ± 5.7 < 0.001
White, n (%) 16 (84.2) 182 (76.5) 0.47
Weight, kg 65.5 ± 9.4 69.7 ± 14.8 0.09
Height, cm 158.9 ± 5.0 160.0 ± 7.0 0.38
Abdominal circumference, cm 84.5 ± 9.8 93.6 ± 15.7 0.02
BMI, kg/m² 25.5 ± 4.6 27.4 ± 6.7 0.22
Arterial hypertension, n (%) 7 (36.8) 147 (62.0) 0.03
Diabetes mellitus, n (%) 0 48 (20.3) 0.03
Dyslipidemia, n (%) 6 (31.6) 69 (29.1) 0.82
Smoking, n (%) 13 (68.4) 169 (71.0) 0.78
Family history of CAD, n (%) 4 (21.1) 87 (36.7) 0.17
Functional class Killip 3 or 4, n (%) 2 (10.5) 23 (9.6) 0.91
Previous AMI, n (%) 1 (5.3) 35 (14.7) 0.29
Previous PCI, n (%) 1 (5.3) 23 (9.7) 0.49
Previous CABG, n (%) 0 4 (1.7) 0.52
Previous stroke, n (%) 0 9 (3.8) 0.42
Heart failure, n (%) 0 9 (3.8) 0.42
Chronic renal failure, n (%) 1 (5.3) 5 (2.1) 0.50
Depression, n (%) 5 (26.3) 60 (25.2) 0.60
Chronic treatment with ASA, n (%) 1 (5.3) 35 (14.7) 0.29
Ejection fraction at the echocardiogram, % 62 ± 12 54 ± 15 0.41
Delta T, hours 4.00 [1.25-6.86] 4.50 [2.50-7.64] 0.54
Door-to-balloon time, hours 1.41 [0.58-1.73] 1.16 [0.91-1.51] 0.02
OC: oral contraceptives; BMI: body mass index; CAD: coronary artery disease; AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass surgery; ASA: acetyl 
salicylic acid.
Table 2
Angiographic and procedural characteristics. 
Characteristics OC 
n = 19
Without OC 
n = 238
p-value
Femoral access, n (%) 13 (68.4) 139 (58.4) 0.59
6 F sheath, n (%) 16 (84.2) 224 (94.1) 0.12
Three-vessel involvement, n (%) 1 (5.3) 25 (10.5) 0.45
LMCA lesion, n (%) 0 6 (2.5) 0.65
EF at ventriculography, % 60.0 ± 0.0 51.0 ± 15.2 0.41
Bifurcation lesion, n (%) 3 (15.8) 32 (13.4) 0.62
Thrombus, n (%) 12 (63.2) 136 (57.1) 0.61
Calcification, n (%) 2 (10.5) 13 (5.5) 0.44
Pre-dilation, n (%) 8 (42.1) 132 (55.5) 0.36
Thrombus aspiration, n (%) 8 (52.6) 61 (25.6) 0.04
Stent implant, n (%) 14 (73.6) 207 (86.9) 0.22
Post-dilation, n (%) 5 (26.3) 61(25.6) 0.95
Kissing-balloon, n (%) 0 9 (3.8) 0.68
Glycoprotein IIb/IIIa, n (%) 8 (42.1) 65 (27.3) 0.17
Clopidogrel 600 mg, n (%) 16 (84.2) 206 (86.6) 0.55
IAB, n (%) 2 (10.5) 10 (4.2) 0.42
Pacemaker, n (%) 0 7 (2.9) 0.69
Reference diameter, mm 3.27 ± 0.42 3.19 ± 1.80 0.87
Stent diameter, mm 3.27 ± 0.38 3.06 ± 0.51 0.13
Stent length, mm 19.5 ± 3.3 19.9 ± 6.5 0.78
Stenosis, %
Pre 95 ± 12 97 ± 8 0.58
Post 5.9 ± 24.3 2.6 ± 13.3 0.80
Coronary flow, n (%)
TIMI 0 pre 12 (63.2) 155 (65.1) 0.98
TIMI 3 post 16 (84.2) 202 (84.9) 0.81
Myocardial perfusion, n (%)
Blush 0 pre 14 (73.7) 168 (70.6) 0.74
Blush 3 post 10 (52.6) 164 (68.9) 0.33
OC: oral contraceptives; LMCA: left main coronary artery; EF: ejection fraction; IAB: intra-aortic balloon; TIMI: Thrombolysis in Myocardial Infarction.
tween the groups (4.00 [1.25 to 6.86] hours vs. 4.50 [2.50 to 7.64] 
hours; p = 0.54), but the door-to-balloon time was longer in pa-
tients using OC (1.41 [0.58 to 1.73] hour vs. 1.16 [0.91 to 1.51] 
hour; p = 0.02).
Regarding the angiographic and procedure characteristics, the groups 
were similar in most characteristics (Table 2). The femoral access was the 
most often used (68.4% vs. 58.4%; p = 0.59), as well as the 6 F sheath 
(84.2% vs. 94.1%; p = 0.12). A minority of patients had three-vessel invol-
vement (5.3% vs. 10.5%; p = 0.45) and preserved left ventricular ejection 
fraction (60.0 ± 0.0% vs. 51.0 ± 15.2%; p = 0.41). The treated vessels had a 
reference diameter of 3.27 ± 0.42 mm vs. 3.19 ± 1.80 mm 
 (p = 0.87), percentage of stenosis of 95 ± 12% vs. 97 ± 8% (p = 0.58), and 
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The lower mean age and the fewer number of comorbidities in 
women using OC were similar to those described in previous stu-
dies, and could be explained by differences in the pathophysiology 
of AMI in both groups. In women using OC, the influence of throm-
bosis would be greater, whereas in those who did not use OC, the 
natural progression of atherosclerosis with atherosclerotic plaque 
rupture and/or erosion, associated with increased cardiovascular 
risk by multiple risk factors, would have a leading role.1,9
Recently, Karabay et al.10 evaluated women submitted to primary 
PCI using fourth-generation OC and demonstrated greater thrombo-
tic burden, lower incidence of final TIMI 3 flow, and more frequent 
multivessel thrombosis. In the present study, the rate of angiogra-
phically visible thrombus in the two groups was not statistically di-
fferent, but no dedicated score was used to assess thrombotic 
burden. However, a very significant difference was found regarding 
the use of thrombus aspiration, which was two times higher in wo-
men using OC; that, in turn, would suggest that the criteria used to 
define thrombus were not sensitive enough to detect a significant 
difference. The observation of elevated C-reactive protein levels in 
women using OC suggests an increase in the inflammatory status of 
these patients, which has already been demonstrated in the study by 
Zakharova et al.11
OC have been used in clinical practice for family planning for 
more than 60 years. Since then, great advances have been made 
regarding therapeutic options, doses, and safety of used formula-
tions.12 However, women in special clinical situations and/or in the 
Thrombolysis in Myocardial Infarction (TIMI) f low 0 in 63.2% vs. 
65.1% (p = 0.98). A visible thrombus was detected in 63.2% vs. 57.1% 
(p = 0.61) of cases and thrombus aspiration was most often perfor-
med in the group of women using OC (52.6% vs. 25.6%; p = 0.04). TIMI 
3 post flow was obtained in 84.2% vs. 84.9% (p = 0.81).
Table 3 compares the laboratory parameters between groups. Wo-
men using OC had higher levels of C-reactive protein and fibrinogen.
Table 4 shows the clinical outcomes. During the in-hospital pha-
se, there were no differences regarding MACE or its individual 
components, only higher occurrence of minor bleeding in patients 
using OC. During the 2-year follow-up, there were no clinical 
events after hospital discharge in the group using OC, with the ex-
ception of one case of very late stent thrombosis. The other group 
had a cumulative event occurrence resulting in a tendency to a hi-
gher MACE (0 vs. 15.2%; p = 0.08).
Discussion
Women using OC referred to primary PCI had less severe clinical 
profile than women of reproductive age who do not use OC, but 
had higher levels of inf lammatory and thrombogenic markers. 
They were submitted to myocardial reperfusion at a later date and 
required more thrombus aspiration procedures. After the index 
event, they tended  to not have new atherothrombotic events in up 
to 2 years of follow-up.
Table 3
Laboratory characteristics.
Characteristics OC 
n = 19
Without OC 
n = 238
p-value
Total cholesterol, mg/dL 235.7 ± 80.0 212.0 ± 69.5 0.22
HDL cholesterol, mg/dL 45.0 ± 12.3 42.5 ± 11.5 0.44
Triglycerides, mg/dL 176 [68-236] 122 [81-170] 0.27
Creatinine, mg/dL 0.72 ± 0.19 0.82 ± 0.95 0.66
Glucose, mg/dL 145.2 ± 63.7 172.8 ± 85.0 0.22
CK, U/L 240 [49-432] 193 [76-736] 0.48
CK-MB, ng/mL 16 [5-52] 18 [8-60] 0.21
Ultrasensitive troponin, pg/mL 401 [97-5,727] 299 [64-2,019] 0.51
C-reactive protein, mg/dL 1.61 [0.65-3.44] 0.55 [0.26-1.28] 0.03
Fibrinogen, mg/dL 317.2 ± 107.2 250.4 ± 88.9 0,03
OC: oral contraceptives; HDL: high density lipoprotein; CK: creatine kinase; CK-MB: creatine kinase MB isoenzyme.
Table 4
Clinical data.
Characteristics OC 
n = 19
Without OC 
n = 238
p-value
In-hospital
MACE, n (%) 0 17 (7.4) 0.62
Death, n (%) 0 15 (6.6) > 0.99
Recurrent AMI, n (%) 0 3 (1.3) > 0.99
Ischemic stroke, n (%) 0 0 NA
Stent thrombosis, n (%) 0 3 (1.3) > 0.99
Major bleeding, n (%) 0 3 (1.3) > 0.99
Minor bleeding, n (%) 3 (15.8) 9 (3.8) 0.049
ARF, n (%) 1 (5.3) 7 (3.0) 0.46
1 year
MACE, n (%) 0 28 (12.2) 0.24
Death, n (%) 0 19 (8.3) 0.38
Recurrent AMI, n (%) 0 7 (2.8) > 0.99
Ischemic stroke, n (%) 0 1 (0.5) > 0.99
Stent thrombosis, n (%) 0 5 (2.2) > 0.99
2 years
MACE, n (%) 0 35 (15.2) 0.08
Death, n (%) 0 21 (9.2) 0.38
Recurrent AMI, n (%) 0 8 (3.8) > 0.99
Ischemic stroke, n (%) 0 2 (0.9) > 0.99
Stent thrombosis, n (%) 1 (5.3) 6 (2.8) 0.42
OC: oral contraceptives; MACE: major cardiovascular events; AMI: acute myocardial infarction; NA: not applicable; ARF: acute renal failure.
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presence of comorbidities require attention regarding the use of 
hormonal contraceptives. In the present study, among the women 
with AMI who used OC, 68.4% were smokers, 36.8% were hyperten-
sive, and 5.3% had a previous AMI – clinical conditions that classify 
the use of OC as category 3 (risks outweigh the benefits) or 4 (unac-
ceptable use), according to the eligibility criteria for use of contra-
ceptive methods of the World Health Organization.13 Thus, these 
findings emphasize the importance of careful assessment and 
identification of cardiovascular risk factors when choosing and 
prescribing OC.
Furthermore, the probable suspension of these drugs after the 
acute coronary episode contributed to the rare occurrence of other 
atherothrombotic events in up to 2 years of follow-up, which did not 
happen in the other group, with a more severe cardiovascular risk 
profile and cumulative occurrence of new events, which resulted in 
a higher MACE. 
In the present study, there was no available information on the 
oral contraceptive formulation, dose, or type of estrogen or proges-
togen that the patients used, which can be considered a limitation of 
this analysis. Data were prospectively collected by a team of dedica-
ted researchers, but the decision to analyze and compare users and 
non-users of OC was performed retrospectively and based on medi-
cal records. More accurate analyses of thrombotic burden through 
dedicated scores or optical coherence tomography were not availab-
le, and can also be considered limitations of the present analysis. The 
number of patients using OC included in this study was small, al-
though it can be favorably compared with several reports in the lite-
rature.10
Conclusions
Women who use oral contraceptives submitted to primary per-
cutaneous coronary intervention were younger and had fewer tradi-
tional risk factors for coronary artery disease than those who did not 
use oral contraceptives, in addition to having higher serum levels of 
fibrinogen and C-reactive protein. They underwent myocardial re-
perfusion at a later stage and required more thrombus aspiration 
procedures. After the index event, they tended to not have athero-
thrombotic outcomes in up to 2 years of follow-up. Studies with a 
larger number of patients are required to confirm these results.
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